These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 11165113)

  • 1. Activity of gatifloxacin and ciprofloxacin in combination with other antimicrobial agents.
    Gradelski E; Kolek B; Bonner DP; Valera L; Minassian B; Fung-Tomc J
    Int J Antimicrob Agents; 2001 Feb; 17(2):103-7. PubMed ID: 11165113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Susceptibility of bacterial isolates to gatifloxacin and ciprofloxacin from clinical trials 1997-1998.
    Huczko E; Conetta B; Bonner D; Valera L; Stickle T; Macko A; Fung-Tomc J
    Int J Antimicrob Agents; 2000 Dec; 16(4):401-5. PubMed ID: 11118848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of gatifloxacin against strains resistant to ofloxacin and ciprofloxacin and its ability to select for less susceptible bacterial variants.
    Fung-Tomc J; Gradelski E; Huczko E; Minassian B; Bonner DP
    Int J Antimicrob Agents; 2001 Jul; 18(1):77-80. PubMed ID: 11463531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative killing rates of gatifloxacin and ciprofloxacin against 14 clinical isolates: impact of bacterial strain and antibiotic concentration.
    Pendland SL; Neuhauser MM; Garey KW; Prause JL; Jung R
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):59-61. PubMed ID: 12376032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative antimicrobial activity of gatifloxacin with ciprofloxacin and beta-lactams against gram-positive bacteria.
    Bassetti M; Dembry LM; Farrel PA; Callan DA; Andriole VT
    Diagn Microbiol Infect Dis; 2001 Nov; 41(3):143-8. PubMed ID: 11750168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone.
    Otani T; Tanaka M; Ito E; Kurosaka Y; Murakami Y; Onodera K; Akasaka T; Sato K
    Antimicrob Agents Chemother; 2003 Dec; 47(12):3750-9. PubMed ID: 14638477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2004). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Matsukawa M; Kunishima Y; Hirose T; Shigeta S; Yamaguti O; Ishibashi K; Suzutani T; Yoshida H; Imafuku Y; Murai M; Watanabe K; Kobayashi Y; Uchida H; Matsuda S; Sato S; Fujime M; Fujita K; Igari J; Oguri T; Yamaguchi K; Furuya N; Deguchi T; Ishihara S; Ooe H; Oka T; Kitamura M; Fukuhara Y; Kamidono S; Arakawa S; Kumon H; Monden K; Matsumoto T; Muratani T; Naito S; Egashira T; Konishi T; Kohno S; Hirakata Y; Kondo A; Matsuda J; Nakano M
    Jpn J Antibiot; 2006 Jun; 59(3):177-200. PubMed ID: 16913404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial activity and accumulation of moxifloxacin in quinolone-susceptible bacteria.
    Piddock LJ; Jin YF
    J Antimicrob Chemother; 1999 May; 43 Suppl B():39-42. PubMed ID: 10382874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antibacterial activity of gatifloxacin against various fresh clinical isolates in 2002].
    Matsuzaki K; Watabe E; Yoshimori K; Shikano M; Sato Y; Hasegawa M; Kobayashi I
    Jpn J Antibiot; 2002 Dec; 55(6):800-7. PubMed ID: 12621734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparative in vitro activity of garenoxacin (BMS-284756). Sentry program, Spain (1999-2000)].
    Loza E; Cantón R; Pascual A; Tubau F; Morosini MI; Almaraz F; Perea E; Martín R; Jones RN; Baquero F
    Enferm Infecc Microbiol Clin; 2003 Oct; 21(8):404-9. PubMed ID: 14525705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and gentamicin against multidrug-resistant organisms.
    Dawis MA; Isenberg HD; France KA; Jenkins SG
    J Antimicrob Chemother; 2003 May; 51(5):1203-11. PubMed ID: 12697632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone.
    Dalhoff A; Petersen U; Endermann R
    Chemotherapy; 1996; 42(6):410-25. PubMed ID: 8957575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergy of fluoroquinolones with other antimicrobial agents.
    Neu HC
    Rev Infect Dis; 1989; 11 Suppl 5():S1025-35. PubMed ID: 2505355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones.
    Wise R; Brenwald NP; Andrews JM; Boswell F
    J Antimicrob Chemother; 1997 Apr; 39(4):447-52. PubMed ID: 9145816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms.
    Sweeney MT; Zurenko GE
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1902-6. PubMed ID: 12760865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg) versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose.
    Boy D; Well M; Kinzig-Schippers M; Sörgel F; Ankel-Fuchs D; Naber KG
    Int J Antimicrob Agents; 2004 Mar; 23 Suppl 1():S6-16. PubMed ID: 15037323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microbiology at first visit of moderate-to-severe diabetic foot infection with antimicrobial activity and a survey of quinolone monotherapy.
    Tascini C; Piaggesi A; Tagliaferri E; Iacopi E; Fondelli S; Tedeschi A; Rizzo L; Leonildi A; Menichetti F
    Diabetes Res Clin Pract; 2011 Oct; 94(1):133-9. PubMed ID: 21824673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postantibiotic effects of E-4868 and OPC-17116.
    Sanford MD; Jones RN
    J Antimicrob Chemother; 1993 Dec; 32(6):916-7. PubMed ID: 8144440
    [No Abstract]   [Full Text] [Related]  

  • 19. In-vitro and in-vivo activities of DW-116, a new fluoroquinolone.
    Choi KH; Hong JS; Kim SK; Lee DK; Yoon SJ; Choi EC
    J Antimicrob Chemother; 1997 Apr; 39(4):509-14. PubMed ID: 9145824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of amikacin, ertapenem, ciprofloxacin and levofloxacin alone and in combination against resistant nosocomial pathogens by time-kill.
    Hosgor-Limoncu M; Ermertcan S; Tasli H; Yurtman AN
    West Indian Med J; 2008 Mar; 57(2):106-11. PubMed ID: 19565951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.